title: Antimicrobial Susceptibility Monitoring of Bacterial Pathogens Isolated from Urinary Tract Infections in Dogs and Cats Across Europe: ComPath Results.
abstract: ComPath is a pan-European antimicrobial surveillance program collecting bacterial pathogens from dogs and cats not recently exposed to antimicrobials. We present minimum inhibitory concentration data obtained using Clinical and Laboratory Standards Institute methodology for 616 urinary tract infection (UTI) isolates collected between 2008 and 2010. In both dogs and cats, the most common pathogen was Escherichia coli (59.8% and 46.7%, respectively). Antimicrobial activity against E. coli in dogs and cats was similar with fluoroquinolone and trimethoprim/sulfamethoxazole susceptibility >90%. Ampicillin susceptibility was ∼80%. Staphylococcus intermedius Group isolates from dogs (67/437, 15.3%) had high antimicrobial susceptibility (>90%) toward beta-lactams, fluoroquinolones, and trimethoprim/sulfamethoxazole. Four canine isolates (6%) were oxacillin resistant, and harbored mecA. Proteus mirabilis from dogs (48/437, 11.0%) had high antimicrobial susceptibility (∼90%) to amoxicillin/clavulanic acid, enrofloxacin, and marbofloxacin and slightly lower susceptibility (∼80-85%) to ampicillin and orbifloxacin. Streptococcus canis isolates (35/437, 8.0%) from dogs were all susceptible to ampicillin and amoxicillin/clavulanic acid and >90% susceptible to marbofloxacin. Although resistance was not observed, high intermediate susceptibility was seen for both enrofloxacin (28.6%) and orbifloxacin (85.7%). Overall, antimicrobial in vitro activity appears to be high in UTI pathogens from dogs and cats with low multidrug resistance, although a lack of specific dog and cat breakpoints for important antimicrobials such as cefovecin, cephalexin, and ibafloxacin prevents analysis of susceptibility for these agents.
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Hilde
authors.initials: H
authors.lastname: Moyaert
authors.affiliation: 2 IHMA Europe Sàrl , Monthey, Switzerland .
authors.forename: Ian
authors.initials: I
authors.lastname: Morrissey
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Anno
authors.initials: A
authors.lastname: de Jong
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Farid
authors.initials: F
authors.lastname: El Garch
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Ulrich
authors.initials: U
authors.lastname: Klein
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Carolin
authors.initials: C
authors.lastname: Ludwig
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Julien
authors.initials: J
authors.lastname: Thiry
authors.affiliation: 1 CEESA ComPath Study Group , Brussels, Belgium .
authors.forename: Myriam
authors.initials: M
authors.lastname: Youala
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002371:Cat Diseases / Q000188:drug therapy* / Q000382:microbiology*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology*; D004285:Dogs; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005060:Europe; D008826:Microbial Sensitivity Tests / Q000379:methods; D011513:Proteus mirabilis / Q000187:drug effects; D057789:Staphylococcus intermedius / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents
keywords: antimicrobial resistance; companion animals; surveillance